Morgan Stanley’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.5M | Sell |
2,337,096
-235,558
| -9% | -$1.5M | ﹤0.01% | 3162 |
|
|
2026
Q1 | $14.9M | Sell |
2,572,654
-135,129
| -5% | -$896K | ﹤0.01% | 3220 |
|
|
2025
Q4 | $21.3M | Sell |
2,707,783
-511,918
| -16% | -$4.03M | ﹤0.01% | 2885 |
|
|
2025
Q3 | $26.2M | Sell |
3,219,701
-422,883
| -12% | -$2.81M | ﹤0.01% | 2622 |
|
|
2025
Q2 | $17M | Sell |
3,642,584
-645,697
| -15% | -$2.96M | ﹤0.01% | 2971 |
|
|
2025
Q1 | $23.5M | Buy |
4,288,281
+1,410,765
| +49% | +$5.69M | ﹤0.01% | 2528 |
|
|
2024
Q4 | $9.75M | Buy |
2,877,516
+523,208
| +22% | +$1.68M | ﹤0.01% | 3438 |
|
|
2024
Q3 | $6.71M | Buy |
2,354,308
+744,384
| +46% | +$1.91M | ﹤0.01% | 3728 |
|
|
2024
Q2 | $3.62M | Buy |
1,609,924
+318,966
| +25% | +$643K | ﹤0.01% | 4145 |
|
|
2024
Q1 | $2.85M | Buy |
1,290,958
+69,600
| +6% | +$180K | ﹤0.01% | 4351 |
|
|
2023
Q4 | $2.87M | Buy |
1,221,358
+583,126
| +91% | +$1.08M | ﹤0.01% | 4288 |
|
|
2023
Q3 | $1.19M | Buy |
638,232
+306,845
| +93% | +$703K | ﹤0.01% | 4697 |
|
|
2023
Q2 | $868K | Buy |
331,387
+177,047
| +115% | +$451K | ﹤0.01% | 4917 |
|
|
2023
Q1 | $252K | Buy |
154,340
+35,582
| +30% | +$44.5K | ﹤0.01% | 5601 |
|
|
2022
Q4 | $158K | Buy |
118,758
+1,188
| +1% | +$1.68K | ﹤0.01% | 5766 |
|
|
2022
Q3 | $185K | Sell |
117,570
-9,641
| -8% | -$15.9K | ﹤0.01% | 5760 |
|
|
2022
Q2 | $195K | Sell |
127,211
-13,318
| -9% | -$28.1K | ﹤0.01% | 5917 |
|
|
2022
Q1 | $360K | Sell |
140,529
-1,210,258
| -90% | -$2.96M | ﹤0.01% | 5585 |
|
|
2021
Q4 | $3.96M | Buy |
1,350,787
+1,104,830
| +449% | +$2.39M | ﹤0.01% | 3961 |
|
|
2021
Q3 | $603K | Buy |
245,957
+97,992
| +66% | +$285K | ﹤0.01% | 5371 |
|
|
2021
Q2 | $602K | Sell |
147,965
-168,249
| -53% | -$642K | ﹤0.01% | 5409 |
|
|
2021
Q1 | $1.43M | Buy |
316,214
+275,064
| +668% | +$1.48M | ﹤0.01% | 4504 |
|
|
2020
Q4 | $202K | Buy |
41,150
+30,292
| +279% | +$152K | ﹤0.01% | 5588 |
|
|
2020
Q3 | $64K | Sell |
10,858
-32,045
| -75% | -$128K | ﹤0.01% | 5625 |
|
|
2020
Q2 | $114K | Buy |
42,903
+39,748
| +1,260% | +$138K | ﹤0.01% | 5342 |
|
|
2020
Q1 | $6K | Sell |
3,155
-41,635
| -93% | -$179K | ﹤0.01% | 6160 |
|
|
2019
Q4 | $315K | Buy |
44,790
+36,905
| +468% | +$305K | ﹤0.01% | 5184 |
|
|
2019
Q3 | $78K | Buy |
7,885
+7,362
| +1,408% | +$82.7K | ﹤0.01% | 5532 |
|
|
2019
Q2 | $6K | Sell |
523
-52,593
| -99% | -$552K | ﹤0.01% | 6280 |
|
|
2019
Q1 | $534K | Buy |
53,116
+42,406
| +396% | +$543K | ﹤0.01% | 4506 |
|
|
2018
Q4 | $182K | Sell |
10,710
-2,676
| -20% | -$53.7K | ﹤0.01% | 5317 |
|
|
2018
Q3 | $235K | Buy |
13,386
+12,663
| +1,751% | +$275K | ﹤0.01% | 5377 |
|
|
2018
Q2 | $13K | Buy |
+723
| New | +$14.1K | ﹤0.01% | 6245 |
|
Other funds holding XERS
RA
Morgan Stanley's XERS Position: Q2 2026 in Review
Morgan Stanley reduced its Xeris Biopharma Holdings (XERS) stake by 9.2% in Q2 2026, selling an estimated $1.5M and leaving 2,337,096 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3162.
Morgan Stanley first reported a position in XERS in Q2 2018 and has held it in 33 quarters since. The position peaked at $26.2M in Q3 2025. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- Morgan Stanley held 2,337,096 shares of Xeris Biopharma Holdings worth $18.5M as of Q2 2026.
- Morgan Stanley sold 235,558 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.5M.
- Xeris Biopharma Holdings made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3162 holding.
- Morgan Stanley first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 33 quarters since.
- Morgan Stanley's Xeris Biopharma Holdings position peaked at $26.2M in Q3 2025.
- 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.